https://www.selleckchem.com/products/c25-140.html
We aimed to characterize serine protease inhibitor Kazal type 1 ( ) as a gene signature for the early diagnosis, molecular targeting, and prediction of immune checkpoint blockade (IC treatment response of hepatocellular carcinoma (HCC). The transcriptomics, proteomics, and phenotypic analyses were performed separately or in combination. We obtained the following findings on . Firstly, in the transcriptomic training dataset, which included 279 stage I and II tumor samples (out of 1,884 stage I-IV HCC specimens) and 259 normal samples,
Like
Comment
Share
